These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14671866)

  • 21. Choice and equity: lessons from long term care.
    Deeming C; Keen J
    BMJ; 2004 Jun; 328(7453):1389-90. PubMed ID: 15191956
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bayer Schering Pharma--support stipend for 2008].
    Rofo; 2008 Jul; 180(7):685. PubMed ID: 18561073
    [No Abstract]   [Full Text] [Related]  

  • 23. The pharmaceutical price regulation scheme.
    Collier J
    BMJ; 2007 Mar; 334(7591):435-6. PubMed ID: 17332539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hastening slowly: Mr Dobson plays a waiting game.
    Klein R
    BMJ; 1997 Oct; 315(7114):966. PubMed ID: 9365288
    [No Abstract]   [Full Text] [Related]  

  • 25. Social insurance--the right way forward for health care in the United Kingdom? Against.
    McKee M; Dixon A; Mossialos E
    BMJ; 2002 Aug; 325(7362):488-90. PubMed ID: 12211229
    [No Abstract]   [Full Text] [Related]  

  • 26. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 27. Big pharma under the spotlight.
    Farham B
    S Afr Med J; 2013 May; 103(6):352. PubMed ID: 23725968
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 29. Risky business.
    Ment Health Today; 2005 May; ():12-3. PubMed ID: 15938578
    [No Abstract]   [Full Text] [Related]  

  • 30. Andrew Witty: the acceptable face of big pharma? Interviewed by Rebecca Coombes.
    Witty A
    BMJ; 2013 Mar; 346():f1458. PubMed ID: 23468295
    [No Abstract]   [Full Text] [Related]  

  • 31. Financing health care: lessons from abroad.
    Maxwell RJ
    Br Med J (Clin Res Ed); 1988 May; 296(6634):1423-6. PubMed ID: 3132274
    [No Abstract]   [Full Text] [Related]  

  • 32. ISTC programme is an expensive option.
    Kelly SP; Billington B; Smith R; Daniel R
    BMJ; 2007 Feb; 334(7587):222. PubMed ID: 17272536
    [No Abstract]   [Full Text] [Related]  

  • 33. Psychiatry has effectively become a commodity that is being sold to the drug industry.
    Timimi S
    Ment Health Today; 2005 Jun; ():21. PubMed ID: 15999409
    [No Abstract]   [Full Text] [Related]  

  • 34. Science, money, and industry: is commerce corrupting AIDS research?
    Mirken B
    BETA; 2002; 15(2):40-4. PubMed ID: 12064305
    [No Abstract]   [Full Text] [Related]  

  • 35. NHS finances: Farewell to dodging and weaving.
    Timmins N
    BMJ; 2007 Apr; 334(7599):877-8. PubMed ID: 17463457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Careful use of science to advance the debate on the UK Cancer Drugs Fund.
    Lakdawalla DN; Jena AB; Doctor JN
    JAMA; 2014 Jan; 311(1):25-6. PubMed ID: 24381964
    [No Abstract]   [Full Text] [Related]  

  • 37. Private finance initiative. About the size of it.
    Ward S
    Health Serv J; 2000 Mar; 110(5698):suppl 4, 7. PubMed ID: 11183711
    [No Abstract]   [Full Text] [Related]  

  • 38. An integrated national pharmaceutical policy for the United Kingdom?
    Walley T; Earl-Slater A; Haycox A; Bagust A
    BMJ; 2000 Dec; 321(7275):1523-6. PubMed ID: 11118184
    [No Abstract]   [Full Text] [Related]  

  • 39. On the grim reality.
    Plumridge N
    Health Serv J; 2009 Feb; 119(6145):17. PubMed ID: 19326536
    [No Abstract]   [Full Text] [Related]  

  • 40. New agreement on branded drugs for the NHS.
    Naci H; Dixon J
    BMJ; 2019 Jan; 364():l266. PubMed ID: 30658964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.